Navigation Links
New robotic head and neck cancer surgery preserves speech, without scarring
Date:9/7/2010

DETROIT An incisionless robotic surgical procedure is offering patients a new option to remove certain head and neck cancer tumors without visible scarring, while preserving speech and the ability to eat.

Henry Ford Hospital in Detroit is among the first in the country to perform TransOral Robotic Surgery (TORS) using the da Vinci Surgical System. Unlike traditional surgical approaches to head and neck cancer, TORS patients are able to return to their normal lives only a few days after surgery without significant pain and disfigurement.

"TORS offers shorter post-operative recovery than standard open surgical approaches, giving patients the opportunity to quickly and successfully return to their normal lives," says Tamer A. Ghanem, M.D., Ph.D., director of Head and Neck Oncology and Reconstructive Surgery Division in the Department of OtolaryngologyHead & Neck Surgery at Henry Ford Hospital.

"TORS allows surgeons to completely remove tumors of the head and neck while preserving speech, swallowing, and other key quality of life issues such as eating. There also is no visible scaring or disfigurement."

Led by Dr. Ghanem, Henry Ford Hospital has performed more than a dozen TORS procedures since it was approved in January by the U.S. Food and Drug Administration to remove malignant and benign tumors of the mouth, tongue, tonsils, and parts of the throat.

Prior to TORS, patients would traditionally begin treatment with radiation therapy, or a combination of chemotherapy and radiation therapy, depending on the stage of their cancer. Side effects of radiation dry mouth, loss of taste and difficulty swallowing can potentially be avoided with TORS

Traditional surgery has side effects as well. It requires a long incision be made across the lip and jaw to access the tumor. This approach can results in significant swelling, longer post-operative recovery, damage to surrounding structures, and speech and swallowing problems.

With TORS, surgeons can access tumors through the mouth using the slender operating arms of the da Vinci, thus not requiring an open skin incision.

"Surgeons operate with greater precision and control using the TORS approach," says Dr. Ghanem, "minimizing the pain, and reducing the risk of possible nerve and tissue damage associated with large incisions."

Some of TORS's other benefits include:

  • Significantly less blood loss
  • No visible scarring
  • Possibility of avoiding a tracheotomy
  • Minimization or elimination of need for chemoradiation therapy
  • Fewer complications and shorter hospital stay
  • Faster recovery, return to normal speech and swallowing
  • Equivalent cancer control to radiation therapy

Patients with early stage tonsil and base of tongue cancers may not need to receive radiation therapy following TORS, depending on the final tumor margins and pathological characteristics of the tumor.

In addition to TORS, Dr. Ghanem specializes in complex head and neck oncology cases, offering both cancer resection as well as reconstructive surgery using microvascular techniques (taking tissue from one part of the body and transplanting it to the head and neck areas to improve function and esthetics). In addition, he performs thyroid, parathyroid, and salivary gland surgery, reconstruction after Mohs procedures and robotic-assisted thyroidectomy, in which the incision is made in the arm pit instead of the neck to conceal it.


'/>"/>

Contact: Krista Hopson
khopson1@hfhs.org
313-874-7207
Henry Ford Health System
Source:Eurekalert  

Related medicine news :

1. Pre-emptive pain regimen decreased opioid usage in patients undergoing robotic prostatectomy
2. Robotic-assisted vasectomy reversal offers greater chance of fatherhood
3. Introducing RoSS, a flight simulator for robotic surgery
4. LA BioMed research finds hallucinogen can safely ease anxiety in advanced-stage cancer patients
5. Hallucinogen appears safe, may improve mood among patients with advanced-stage cancer and anxiety
6. Long-Term Use of Bone Drugs May Be Linked to Esophageal Cancer
7. Basal-like breast cancer does not originate from basal stem cells
8. Study finds that cancer-causing gene crucial in stem cell development
9. Microsoft Excel-based algorithm predicts cancer prognosis
10. Diabetes Drug Metformin Linked to Lower Lung Cancer Rate in Mice
11. Targeted strategies needed to find, prevent and treat breast cancer among Mexican-origin women
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New robotic head and neck cancer surgery preserves speech, without scarring
(Date:1/17/2017)... ... January 17, 2017 , ... ... as Palm Desert, is opening a new office in San Clemente, California this ... stimulation (dTMS) in Southern California, successfully treating individuals struggling with major depression. Depression ...
(Date:1/17/2017)... ... January 17, 2017 , ... Peoples Health is pleased ... network on Dec. 1, 2016. Peoples Health, a Metairie-based Medicare Advantage company, serves ... exciting addition to our provider network, and the addition will benefit our members ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... today announced its partnership with Sigfox in the U.S.A. to offer ... nationwide including new offerings on large-scale environmental sensor deployments such as monitoring ...
(Date:1/17/2017)... ... 17, 2017 , ... SC&H Group, a leading audit, tax, and consulting firm, ... IT Advisory Services practice . Rossi is the third technology consulting leader to join ... guidance grows, and the practice continues to expand.     , Bringing more than 25 years ...
(Date:1/17/2017)... ... 17, 2017 , ... Physicians Education Review®, LCC (PER®) announces ... for the 34th Annual Miami Breast Cancer Conference®, on March 9-12, 2017 at ... Talamo, said, “We are delighted to have Sandra Lee join us as our ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... 2017 Following an initial analysis, the ... Food and Drug Administration,s (FDA,s) final regulatory guidance ... by Pharmacies and Outsourcing Facilities." In its final ... pre-packaging -- which would have put patients at ... term care (LTC) pharmacies.  The ...
(Date:1/17/2017)... Research and Markets has announced the addition ... Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormone) Drug (OTC, ... report to their offering. ... The global active pharmaceutical ingredients market is expected ... in 2016, growing at a CAGR of 6.3% from 2016 to ...
(Date:1/17/2017)... , Jan. 17, 2017  In a preview of ... Annual Congress, Astute Medical, Inc., developer of the NephroCheck ... the test, which identifies hospital patients at risk of developing ... take place this month at the Hawaii ... January 21 through January 25. AKI is one ...
Breaking Medicine Technology: